At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MRKR Marker Therapeutics, Inc.
Market Closed 10-04 16:00:00 EDT
2.80
+0.15
+5.52%
盘后2.86
+0.06+2.14%
16:00 EDT
High2.93
Low2.66
Vol8.32K
Open2.66
D1 Closing2.65
Amplitude10.18%
Mkt Cap24.98M
Tradable Cap18.94M
Total Shares8.92M
T/O23.20K
T/O Rate0.12%
Tradable Shares6.76M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
Marker Therapeutics Awarded $2 Million Grant From Nih in Support of Phase 1 Study Investigating Mt-601 in Car-Relapsed Patients With Non-Hodgkin’s Lymphoma
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.